Earlier recognition of bile duct cancer by analyzing bile fluid

The use of intraduodenally sampled bile as a screening tool for cholangiocarcinoma using the PandiCath® catheter; a prospective pilot study - PANDICA-pilot

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON61361

Enrollment

Registered

2026-04-03

Start date

2026-07-01

Completion date

Unknown

Last updated

2026-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary sclerosing cholangitis

Interventions

Sampling bile from the duodenum with the PandiCath® catheter

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 18 years or older Capable of providing written and oral informed consent Primary sclerosing cholangitis or cholangiocarcinomaScheduled for ERCP 

Exclusion criteria

Exclusion criteria: Complete bile duct obstruction  Technical contra-indications for endobiliary drainage (e.g. previous gastrojejunostomy) Allergy to silicones or other components of the catheter Any condition that is unstable or could jeopardize the safety or compliance of the subject 

Design outcomes

Primary

Measure	Time frame
Primary outcome: safety and feasibility of sampling bile from the duodenum with the PandiCath® catheter.	—

Secondary

Measure	Time frame
Secondary outcome: quantity and quality of bile sampled from the duodenum with the PandiCath® catheter compared with intraductally sampled bile.	—

Countries

Netherlands

Contacts

Public ContactE Smit

Amsterdam UMC

e.smit1@amsterdamumc.nl06-48387374

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 23, 2026